“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

21 May 2019
Pharma

Visiongain has launched a new pharma report Urology Devices Market Report: Urinary Incontinence, Benign Prostatic Hyperplasia, Kidney Stone, Prostate Cancer.

In 2018, the urology devices market is estimated at $6.9 billion. The market is expected to grow at a CAGR of 6.1% from 2018 to 2029. Products included in the urology devices market include catheters, slings, brachytherapy, radiation therapy devices, accessories and others. The urinary incontinence market dominated the market in 2018 and accounted for 33.8% of the urology devices market.

The lead analyst of the report commented "The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs. Other factors contributing to the growth of the market are preference for minimally invasive procedures and rising incidence of obesity. The market has certain restraining factors such as high cost of devices and social stigma associated with the disease."

Leading companies featured in the report include C.R. Bard, Coloplast, Endo Pharmaceuticals, Boston Scientific Corporation, Healthtronics, Lumenis, Medtronic, Siemens Healthcare, Urologix and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever